SequelSEC

Tempest Therapeutics, Inc. TPST

Pharmaceutical Preparations · CIK 0001544227 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$295.00K
Fiscal year ended 2017-12-31
Operating income
-$84.33M
Fiscal year ended 2017-12-31
Free cash flow
-$20.34M
Fiscal year ended 2017-12-31

Tempest Therapeutics, Inc. (TPST) reported revenue of $295.00K and net income of -$84.58M for the fiscal year ended 2017-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Tempest Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Tempest Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Revenue$295.00K$653.00K$277.00K$0
Cost of revenue$790.00K$5.40M$2.25M$0
Gross profit-$495.00K-$4.75M-$1.97M$0
Operating income-$84.33M-$81.01M-$72.00M-$47.93M
Net income-$84.58M-$82.26M-$73.22M-$49.52M
Research & development$18.34M$21.64M$18.43M$21.78M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailable
Pretax income-$50.91M-$82.06M-$73.14M-$49.52M
Income tax expense$67.00K$201.00K$75.00K$0
Diluted EPSUnavailableUnavailableUnavailableUnavailable
Selling, general & administrative$27.74M$49.22M$51.59M$26.15M
General & administrative$5.96MUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Tempest Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Cash & equivalents$17.58M$43.93M$43.22M$6.41M
Total assets$19.81M$122.54M$138.61M$65.57M
Current assets$19.74M$116.44M$129.86M$61.88M
Total liabilities$4.83M$14.32M$11.76M$10.25M
Current liabilities$4.09M$13.21M$11.24M$10.17M
Total equity incl. NCI-$128.52M-$51.20M$126.85M$55.32M
Temporary (mezzanine) equity$10.58MUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debt$599.00KUnavailableUnavailableUnavailable
Accounts payable$1.30M$2.18M$3.35M$2.52M

Cash flow

Tempest Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$20.34M-$61.73M-$50.29M-$30.59M
Capital expenditures$4.00K$2.59M$5.23M$2.80M
Investing cash flow$458.00K$8.29M-$38.29M-$32.79M
Financing cash flow-$4.46M$54.15M$125.39M$51.71M
Net change in cash-$24.33MUnavailableUnavailableUnavailable
Stock-based compensation$6.89M$9.22M$19.34M$12.41M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.65M$2.24M$1.29M$450.00K

Derived

Tempest Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2017-12-312016-12-312015-12-312014-12-31
Free cash flow-$20.34M-$64.32M-$55.52M-$33.39M
Gross margin-167.8%-727.1%-711.9%Unavailable
Operating marginUnavailable-12406.1%-25992.4%Unavailable
FCF marginUnavailable-9849.9%-20041.5%Unavailable
SBC / revenue2336.6%1411.2%6980.9%Unavailable
Current ratio4.82x8.82x11.55x6.08x
Revenue YoY growth-54.8%135.7%UnavailableUnavailable
Net marginUnavailable-12597.2%-26432.9%Unavailable
R&D / revenue6215.9%3314.1%6654.5%Unavailable
CapEx / revenueUnavailable396.0%1887.7%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TPST in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2017-12-31

Difference 132922000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2016-12-31

Difference 159420000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.